{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Palma-Chavez JA"],"funding":["American Heart Association","American Heart Association-American Stroke Association","National Cancer Institute","NCI NIH HHS","Qatar National Research Fund","Cancer Prevention and Research Institute of Texas","National Science Foundation"],"pagination":["e2000377"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8203499"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(3)"],"pubmed_abstract":["Vascular-targeted drug delivery remains an attractive platform for therapeutic and diagnostic interventions in human diseases. This work focuses on the development of a poly-lactic-co-glycolic-acid (PLGA)-based multistage delivery system (MDS). MDS consists of two stages: a micron-sized PLGA outer shell and encapsulated drug-loaded PLGA nanoparticles. Nanoparticles with average diameters of 76, 119, and 193 nm are successfully encapsulated into 3-6 µm MDS. Sustained in vitro release of nanoparticles from MDS is observed for up to 7 days. Both MDS and nanoparticles arebiocompatible with human endothelial cells. Sialyl-Lewis-A (sLe<sup>A</sup> ) is successfully immobilized on the MDS and nanoparticle surfaces to enable specific targeting of inflamed endothelium. Functionalized MDS demonstrat"],"journal":["Macromolecular bioscience"],"pubmed_title":["Development and Characterization of PLGA-Based Multistage Delivery System for Enhanced Payload Delivery to Targeted Vascular Endothelium."],"pmcid":["PMC8203499"],"funding_grant_id":["NPRP8‐1606‐3‐322","17SDG33660894","RP180588","1R01CA218739","R01 CA218739","HRD – 1810995"],"pubmed_authors":["Palma-Chavez JA","Applegate BE","Jo JA","Fuentes K","Charoenphol P"],"additional_accession":[]},"is_claimable":false,"name":"Development and Characterization of PLGA-Based Multistage Delivery System for Enhanced Payload Delivery to Targeted Vascular Endothelium.","description":"Vascular-targeted drug delivery remains an attractive platform for therapeutic and diagnostic interventions in human diseases. This work focuses on the development of a poly-lactic-co-glycolic-acid (PLGA)-based multistage delivery system (MDS). MDS consists of two stages: a micron-sized PLGA outer shell and encapsulated drug-loaded PLGA nanoparticles. Nanoparticles with average diameters of 76, 119, and 193 nm are successfully encapsulated into 3-6 µm MDS. Sustained in vitro release of nanoparticles from MDS is observed for up to 7 days. Both MDS and nanoparticles arebiocompatible with human endothelial cells. Sialyl-Lewis-A (sLe<sup>A</sup> ) is successfully immobilized on the MDS and nanoparticle surfaces to enable specific targeting of inflamed endothelium. Functionalized MDS demonstrat","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-04T10:16:18.016Z","creation":"2025-04-04T10:16:18.016Z"},"accession":"S-EPMC8203499","cross_references":{"pubmed":["33393217"],"doi":["10.1002/mabi.202000377"]}}